Drugs A - Z

rosiglitazone Images

Generic Name: rosiglitazone

Brand Names: Avandia

There is an FDA Alert for this drug. Click here to view it.

  • Thiazolidinediones, including rosiglitazone, cause or exacerbate CHF in some patients. Monitor patients for signs and symptoms of CHF (e.g., dyspnea, rapid weight gain, edema) after initiation of therapy and dosage titration. If signs and symptoms of CHF develop, manage disorder according to current standards of care; in addition, consider discontinuance or reduction in dosage of rosiglitazone.
  • Not recommended in patients with symptomatic CHF (NYHA class I or II).
  • Initiation of rosiglitazone in patients with NYHA class III or IV CHF contraindicated. (See Heart Failure and Other Cardiac Effects under Cautions.)

    Myocardial Ischemia
  • Potential risk for myocardial ischemia (e.g., angina, MI); available data on such risk inconclusive. Findings from a meta-analysis of short-term clinical trials (6 months; 42 clinical trials, majority placebo-controlled) indicate the risk of myocardial ischemia is increased in patients receiving rosiglitazone. Data from 3 large long-term clinical trials that compared rosiglitazone with placebo or active comparators did not confirm or exclude this risk.

The Healthline Site, its content, such as text, graphics, images, search results, and other material contained on the Healthline Site ("Content"), its services, and any information or material posted on the Healthline Site by third parties are provided for informational purposes only. None of the foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately. Please read the Terms of Service for more information regarding use of the Healthline Site.